SS
MRSN

Steve Schonfeld’s Mersana Therapeutics MRSN Stock Holding History

Steve Schonfeld’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-273,579
Closed -$2.12M – 2392
2025
Q3 		$2.12M Buy
273,579
+46,625
+21% +$350K 0.01% 1001
2025
Q2 		$1.68M Sell
226,954
-77,609
-25% -$682K 0.01% 1076
2025
Q1 		$2.62M Buy
304,563
+219,780
+259% +$3.39M 0.02% 824
2024
Q4 		$3.03M Sell
84,783
-4,149
-5% -$215K 0.02% 671
2024
Q3 		$4.2M Sell
88,932
-30,145
-25% -$1.33M 0.03% 604
2024
Q2 		$5.98M Buy
119,077
+78,731
+195% +$5.69M 0.04% 499
2024
Q1 		$4.52M Sell
40,346
-5,230
-11% -$520K 0.03% 686
2023
Q4 		$2.64M Buy
+45,576
New +$1.83M 0.02% 709
2023
Q3 		– Sell
-12,822
Closed -$1.05M – 2101
2023
Q2 		$1.05M Buy
+12,822
New +$1.88M 0.01% 946
2022
Q4 		– Sell
-3,446
Closed -$583K – 2863
2022
Q3 		$583K Buy
+3,446
New +$560K ﹤0.01% 1649
2022
Q2 		– Sell
-2,116
Closed -$211K – 2826
2022
Q1 		$211K Buy
+2,116
New +$247K ﹤0.01% 1920
2021
Q3 		– Sell
-900
Closed -$306K – 2354
2021
Q2 		$306K Sell
900
-936
-51% -$354K ﹤0.01% 1461
2021
Q1 		$743K Sell
1,836
-4,297
-70% -$2.08M 0.01% 1002
2020
Q4 		$4.08M Buy
6,133
+2,427
+65% +$1.35M 0.05% 444
2020
Q3 		$1.73M Buy
3,706
+1,729
+87% +$874K 0.03% 546
2020
Q2 		$1.16M Buy
1,977
+357
+22% +$122K 0.03% 569
2020
Q1 		$236K Buy
1,620
+1,200
+286% +$210K 0.01% 850
2019
Q4 		$60K Buy
+420
New +$30.7K ﹤0.01% 1228
2018
Q2 		– Sell
-418
Closed -$165K – 887
2018
Q1 		$165K Buy
+418
New +$165K 0.01% 697
2017
Q3 		– Sell
-1,400
Closed -$489K – 716
2017
Q2 		$489K Buy
+1,400
New +$484K 0.05% 394

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Steve Schonfeld's MRSN Position: Q4 2025 in Review

Steve Schonfeld sold out of Mersana Therapeutics (MRSN) in Q4 2025, closing a stake of 273,579 shares — an estimated $2.12M sold.

Steve Schonfeld first reported a position in MRSN in Q2 2017 and held it in 20 quarters. The position peaked at $5.98M in Q2 2024. 51 funds tracked by Wall St. Rank hold MRSN as of Q4 2025.

  • Steve Schonfeld reported no remaining Mersana Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Steve Schonfeld sold 273,579 Mersana Therapeutics shares in Q4 2025, an estimated $2.12M.
  • Steve Schonfeld first reported a position in Mersana Therapeutics in Q2 2017 and held it in 20 quarters.
  • Steve Schonfeld's Mersana Therapeutics position peaked at $5.98M in Q2 2024.
  • 51 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.